A new market research report on the Global Cardiac
Biomarkers Testing market has introduced by KD Market Insights. The
report is dedicated to in-depth industry analysis of the global Cardiac
Biomarkers Testing market. The Global Cardiac Biomarkers Testing analysis is broken down on
different segmentation levels including Market By Type, By Application, By Location of Testing.
The global cardiac biomarker market generated
$7,638 million in 2018, and is projected to reach $18,232 million by 2026,
growing at a CAGR of 11.4%. Cardiac
biomarkers are protein-based traceable substances used as an indicator of
biologic state as well as for diagnostic and prognostic purposes associated
with heart. The prevention of cardiac diseases by monitoring heart conditions
via cardiac biomarker testing is the profound approach for obtaining rapid
results for immediate diagnosing and treatment. Cardiac biomarkers are used as
risk stratification for various cardiovascular diseases (CVDs), which include
myocardial infraction, congestive heart failure, acute coronary syndrome (ACS),
and others. The cardiac biomarkers that are widely used as an integrated
diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs,
IMA, and others. The global cardiac biomarkers testing market has witnessed a
greater demand over the past five to six years.
The ability of cardiac markers for accurate and rapid prediction
of heart failure after the onset of chest pain acts as a key factor that boosts
the growth of the global cardiac market. In addition, promising features such
as high accuracy, quick outcomes, and economic pricing of cardiac point of care
(POC) testing drive the market growth. To keep the momentum of cardiac marker
tests, key manufacturers offer customized solutions, thus propelling the growth
of the market. The commercial application of multi-menu options for cardiac
testing using different combinations of cardiac biomarkers and target-oriented
solutions serves as the key opportunity for market expansion. However, limited
specificity in some cases and side effects such as skeletal muscle injury
restrains the growth of the cardiac biomarkers testing market.
The
global cardiac biomarker market is segmented based on
type, application, location of testing, and region. By type, the market is
fragmented into myocardial muscle creatine kinase (CK-MB), troponins (T and I),
myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, ischemia modified
albumin (IMA), and others. Depending on application, it is categorized into
myocardial infarction, congestive heart failure, acute coronary syndrome,
atherosclerosis, and others. By location of testing, it is bifurcated into
point of care testing and laboratory testing. Region wise, it is analyzed
across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
-
This report highlights the market dynamics to understand the global cardiac
biomarker market and capitalize on the prevailing opportunities.
- Quantitative analysis of the current market and forecasts assists stakeholders to design business strategies accordingly.
- Porter's five forces analysis examines the competitive market structure and provides a deeper understanding of the influencing factors for entry and expansion.
- Pin-point analysis of geographical segments offers identification of most profitable segments to capitalize on.
- Quantitative analysis of the current market and forecasts assists stakeholders to design business strategies accordingly.
- Porter's five forces analysis examines the competitive market structure and provides a deeper understanding of the influencing factors for entry and expansion.
- Pin-point analysis of geographical segments offers identification of most profitable segments to capitalize on.
KEY MARKET SEGMENTS
By Type
- Myocardial Muscle Creatine Kinase (CK-MB)
- Troponins (T and I)
- Myoglobin
- Brain Natriuretic Peptide (BNPs) or NT-proBNP
- Ischemia-modified Albumin (IMA)
- Others
- Myocardial Muscle Creatine Kinase (CK-MB)
- Troponins (T and I)
- Myoglobin
- Brain Natriuretic Peptide (BNPs) or NT-proBNP
- Ischemia-modified Albumin (IMA)
- Others
By Application
- Myocardial Infarction
- Congestive Heart Failure
- Acute Coronary Syndrome
- Atherosclerosis
- Others
- Myocardial Infarction
- Congestive Heart Failure
- Acute Coronary Syndrome
- Atherosclerosis
- Others
By Location of Testing
- Point of Care Testing
- Laboratory Testing
- Point of Care Testing
- Laboratory Testing
By Region
North
America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- Spain
- Italy
- UK
- Rest of Europe
Asia-Pacific
- Australia
- Japan
- India
- China
- Rest of Asia-Pacific
LAMEA
- Latin America
- Middle East
- Africa
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- Spain
- Italy
- UK
- Rest of Europe
Asia-Pacific
- Australia
- Japan
- India
- China
- Rest of Asia-Pacific
LAMEA
- Latin America
- Middle East
- Africa
KEY MARKET PLAYERS
-
Roche Diagnostics
- Abbott Laboratories
- Siemens Healthcare
- Becton, Dickinson and Company
- Bio-Rad Laboratories
- BioMerieux
- PerkinElmer Inc.
- Tosoh Corporation
- Danaher Corporation
- Thermo Fisher Scientific
- Abbott Laboratories
- Siemens Healthcare
- Becton, Dickinson and Company
- Bio-Rad Laboratories
- BioMerieux
- PerkinElmer Inc.
- Tosoh Corporation
- Danaher Corporation
- Thermo Fisher Scientific
Access Complete Research Report with TOC @ https://www.kdmarketinsights.com/product/cardiac-biomarkers-testing-market-amr
Table of Content
CHAPTER 1: INTRODUCTION
1.1.
Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1.
Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1.
Key findings
2.1.1.
Top impacting factors
2.1.2. Top investment pockets
2.1.2. Top investment pockets
2.2.
CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1.
Market definition and scope
3.2. Biomarker diagnosis vs. conventional diagnosis
3.3. Assessment of key advantages and buying criteria for diagnostic biomarkers
3.2. Biomarker diagnosis vs. conventional diagnosis
3.3. Assessment of key advantages and buying criteria for diagnostic biomarkers
3.3.1.
Early diagnosis
3.3.2. Tissue specific diagnosis
3.3.3. Reduce clinical trials
3.3.4. Consistent output
3.3.2. Tissue specific diagnosis
3.3.3. Reduce clinical trials
3.3.4. Consistent output
3.4.
Key trends impacting the Cardiac biomarker testing market
3.4.1.
Development of high sensitive biomarkers for risk stratification
3.4.2. Technological advancements in the cardiac biomarkers: Serum based biomarkers
3.4.3. Increasing demand for point of care cardiac diagnostics
3.4.2. Technological advancements in the cardiac biomarkers: Serum based biomarkers
3.4.3. Increasing demand for point of care cardiac diagnostics
3.5.
Parent Market Overview
3.6. Key Forces Shaping Cardiac biomarker testing market
3.6. Key Forces Shaping Cardiac biomarker testing market
3.6.1.
High bargaining power of suppliers
3.6.2. Low bargaining power of buyers
3.6.3. Low threat of new entrants
3.6.4. Low threat of substitutes
3.6.5. High intensity of rivalry
3.6.2. Low bargaining power of buyers
3.6.3. Low threat of new entrants
3.6.4. Low threat of substitutes
3.6.5. High intensity of rivalry
3.7.
Value chain analysis
3.8. Pricing Analysis
3.8. Pricing Analysis
3.8.1.
Pricing Analysis, By Region, 2018 & 2025
3.9.
Market evolution/Industry roadmap
3.10. Government regulations
3.11. Reimbursement issues
3.12. Patent Analysis
3.10. Government regulations
3.11. Reimbursement issues
3.12. Patent Analysis
3.12.1.
By Region (2016-2018)
3.12.2. By Applicant
3.12.2. By Applicant
3.13.
Market share analysis
3.14. Case Studies
3.14. Case Studies
3.14.1.
Case Study
3.15.
Market dynamics
3.15.1.
Drivers
3.15.1.1.
Increasing prevalence of cardiovascular diseases
3.15.1.2. Cost effective
3.15.1.3. Non-invasive
3.15.1.4. Accuracy prediction
3.15.1.5. Technological advancements using cardiac biomarkers combinations
3.15.1.6. Increasing point of care (POC) testing
3.15.1.2. Cost effective
3.15.1.3. Non-invasive
3.15.1.4. Accuracy prediction
3.15.1.5. Technological advancements using cardiac biomarkers combinations
3.15.1.6. Increasing point of care (POC) testing
3.15.2.
Restraints
3.15.2.1.
Government Regulation
3.15.2.2. Conformation in result
3.15.2.3. Complex process
3.15.2.2. Conformation in result
3.15.2.3. Complex process
3.15.3.
Opportunities
3.15.3.1.
Personalized medicine
3.15.3.2. Point of care (POCT) testing using cardiac biomarkers
3.15.3.2. Point of care (POCT) testing using cardiac biomarkers
CHAPTER 4: CARDIAC BIOMARKER
TESTING MARKET, BY TYPE
4.1.
Overview
4.1.1.
Market size and forecast
4.2.
Creatine kinase (CK-MB)
4.2.1.
Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3.
Troponins
4.3.1.
Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4.
Myoglobin
4.4.1.
Key market trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5.
Natriuretic peptides (BNP and NT-proBNP)
4.5.1.
Key market trends and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country
4.5.2. Market size and forecast
4.5.3. Market analysis, by country
4.6.
Ischemia modified albumin
4.6.1.
Key market trends and opportunities
4.6.2. Market size and forecast
4.6.3. Market analysis, by country
4.6.2. Market size and forecast
4.6.3. Market analysis, by country
4.7.
Others
4.7.1.
Key market trends and opportunities
4.7.2. Market size and forecast
4.7.3. Market analysis, by country
4.7.2. Market size and forecast
4.7.3. Market analysis, by country
CHAPTER 5: CARDIAC BIOMARKER
TESTING MARKET, BY APPLICATION
5.1.
Overview
5.1.1.
Market size and forecast
5.2.
Myocardial infarction
5.2.1.
Market size and forecast
5.2.2. Market analysis, by country
5.2.2. Market analysis, by country
5.3.
Congestive heart failure
5.3.1.
Market size and forecast
5.3.2. Market analysis, by country
5.3.2. Market analysis, by country
5.4.
Acute coronary syndrome
5.4.1.
Market size and forecast
5.4.2. Market analysis, by country
5.4.2. Market analysis, by country
5.5.
Atherosclerosis
5.5.1.
Market size and forecast
5.5.2. Market analysis, by country
5.5.2. Market analysis, by country
5.6.
Other applications
5.6.1.
Market size and forecast
5.6.2. Market analysis, by country
5.6.2. Market analysis, by country
Continue @...
About Us:
KD Market
Insights offers a
comprehensive database of syndicated research studies, customized reports, and
consulting services. These reports are created to help in making smart, instant
and crucial decisions based on extensive and in-depth quantitative information,
supported by extensive analysis and industry insights. Our dedicated in-house
team ensures the reports satisfy the requirement of the client. We aim at
providing value service to our clients. Our reports are backed by extensive
industry coverage and is made sure to give importance to the specific needs of
our clients. The main idea is to enable our clients to make an informed
decision, by keeping them and ourselves up to date with the latest trends in
the market.
Contact Us:
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: sales@kdmarketinsights.com
Website: www.kdmarketinsights.com
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: sales@kdmarketinsights.com
Website: www.kdmarketinsights.com
This is dummy text. It is not meant to be read. Accordingly, it is difficult to figure out when to end it. But then, this is dummy text. It is not meant to be read. Period.
ConversionConversion EmoticonEmoticon